Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis - Takeaways - MDSpire

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • By

  • Enrique Gómez de la Fuente

  • Enrique Herrera

  • Iñigo Martinez-Espronceda Esquerdo

  • David Vidal Sarró

  • Ignasi Figueras-Nart

  • Juan F. Silvestre Salvador

  • Yolanda Gilaberte

  • Sergio Santos Alarcón

  • Esther Serra-Baldrich

  • Monica Munera Campos

  • Rosa M. Moro

  • Silvia Díaz-Cerezo

  • Sebastian Moyano

  • Irene Talavera-Rodríguez

  • Mercedes Núñez

  • April 21, 2026

  • 0 min

Share

  • 1

    The DAMA-S study evaluated baricitinib treatment patterns and effectiveness in adults with moderate-to-severe atopic dermatitis in Spain.

  • 2

    Baricitinib persistence rates were 85.1%, 75.7%, and 58.4% at weeks 16, 24, and 52, indicating sustained treatment adherence.

  • 3

    By week 16, 69.7% of patients achieved a ≥ 75% improvement in Eczema Area and Severity Index (EASI75) scores.

  • 4

    At week 24, 63.6% of patients reached an Investigator’s Global Assessment (IGA) score of 0 or 1, reflecting significant clinical improvement.

  • 5

    The study highlights baricitinib's effectiveness in routine clinical practice for atopic dermatitis patients in Spain.

Original Source(s)

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

  • by Enrique Gómez de la Fuente, Enrique Herrera, Iñigo Martinez-Espronceda Esquerdo, David Vidal Sarró, Ignasi Figueras-Nart, Juan F. Silvestre Salvador, Yolanda Gilaberte, Sergio Santos Alarcón, Esther Serra-Baldrich, Monica Munera Campos, Rosa M. Moro, Silvia Díaz-Cerezo, Sebastian Moyano, Irene Talavera-Rodríguez, Mercedes Núñez

  • April 21, 2026

Related Content

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Allergen Sensitization in Skin of Color

Scoping review links contact allergy to AD severity

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study